Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Marker Therapeutics (MRKR) Return on Sales (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed Return on Sales for 10 consecutive years, with 7.81% as the latest value for Q4 2025.

  • Quarterly Return on Sales rose 555.0% to 7.81% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.55% through Dec 2025, down 31.0% year-over-year, with the annual reading at 3.43% for FY2025, 180.0% down from the prior year.
  • Return on Sales for Q4 2025 was 7.81% at Marker Therapeutics, up from 1.62% in the prior quarter.
  • The five-year high for Return on Sales was 8.26% in Q4 2023, with the low at 66.41% in Q1 2021.
  • Average Return on Sales over 5 years is 8.03%, with a median of 1.62% recorded in 2025.
  • The sharpest move saw Return on Sales skyrocketed 5626bps in 2022, then plummeted -3295bps in 2023.
  • Over 5 years, Return on Sales stood at 66.41% in 2021, then surged by 98bps to 1.07% in 2022, then surged by 872bps to 8.26% in 2023, then tumbled by -73bps to 2.26% in 2024, then surged by 246bps to 7.81% in 2025.
  • According to Business Quant data, Return on Sales over the past three periods came in at 7.81%, 1.62%, and 4.8% for Q4 2025, Q3 2025, and Q2 2025 respectively.